Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.51 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.51 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1971037 | 0.93 | POLB (0.62) | POLBHPRT1P2RY2P2RY4P2RY6 | |
| SCHEMBL1971043 | 0.93 | POLB (0.62) | POLBHPRT1P2RY2P2RY4P2RY6 | |
| SCHEMBL29616435 | 0.93 | POLB (0.61) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL15329274 | 0.93 | POLB (0.57) | POLBHPRT1P2RY2P2RY4P2RY6 | |
| SCHEMBL16587618 | 0.91 | POLB (0.60) | POLBHPRT1P2RY2P2RY4P2RY6 | |
| SCHEMBL19884490 | 0.91 | POLB (0.60) | POLBHPRT1P2RY2P2RY4P2RY6 | |
| SCHEMBL31651550 | 0.91 | POLB (0.55) | POLBHPRT1P2RY2P2RY4P2RY6 | |
| SCHEMBL24059912 | 0.91 | POLB (0.66) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL5709934 | 0.91 | POLB (0.66) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL17586738 | 0.91 | POLB (0.66) | POLBP2RY2P2RY4P2RY6NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 730 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744669-A2 | APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4714500-A2 | HEPATITIS B VIRUS (HBV) DSRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-12577564-B2 | Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-12565653-B2 | ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-03 | — | — | US | claimed |
| US-12553053-B2 | Transmembrane serine protease 2 (TMPRSS2) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-02-17 | — | — | US | claimed |
| US-12534731-B2 | Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-01-27 | — | — | US | claimed |
| US-12516322-B2 | Microtubule associated protein Tau (MAPT) iRNA agent compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-01-06 | — | — | US | claimed |
| US-12473550-B2 | Coagulation factor V (F5) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-11-18 | — | — | US | claimed |
| US-20250313840-A1 | MUCIN-5B (MUC5B) TARGETED SIRNA AND ANTISENSE OLIGONUCLEOTIDES AND METHODS OF USE THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-10-09 | — | — | US | claimed |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | claimed |
| EP-3387129-A1 | STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2018-10-17 | — | — | EP | claimed |
| US-20180273955-A1 | STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2018-09-27 | — | — | US | claimed |
| US-20180195073-A1 | GLUCOKINASE (GCK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2018-07-12 | — | — | US | claimed |
| CN-107743522-A | angiopoietin-like 3 (ANGPT L3) iRNA compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2018-02-27 | — | — | CN | claimed |
| EP-3221451-A1 | APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2017-09-27 | — | — | EP | claimed |
| US-20170260527-A1 | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2017-09-14 | — | — | US | claimed |
| WO-2017100542-A1 | STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-06-15 | — | — | WO | claimed |
| WO-2016209862-A1 | GLUCOKINASE (GCK) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-12-29 | — | — | WO | claimed |
| WO-2016081444-A9 | APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-07-21 | — | — | WO | claimed |
| WO-2016081444-A1 | APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-05-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180195073-A1 | GLUCOKINASE (GCK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | GCKR, GCK, GBA3 | POLB 400/4885HPRT1 906/4885P2RY2 3439/4885 |
| US-12534731-B2 | Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof | ADRA2A, ADRB2, ADRA2B | POLB 469/4885HPRT1 1055/4885P2RY2 162/4885 |
| US-12553053-B2 | Transmembrane serine protease 2 (TMPRSS2) iRNA compositions and methods of use thereof | TMPRSS2, TMPRSS11D, TMPRSS4 | POLB 1821/4885HPRT1 1484/4885P2RY2 2183/4885 |
| US-20180273955-A1 | STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | SREBF1, SREBF2, FABP1 | POLB 1487/4885HPRT1 3625/4885P2RY2 4748/4885 |
| US-12577564-B2 | Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof | SREBF1, SREBF2, ATF4 | POLB 2465/4885HPRT1 2234/4885P2RY2 4392/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | POLB 712/4885HPRT1 1213/4885P2RY2 3116/4885 |
| US-12473550-B2 | Coagulation factor V (F5) iRNA compositions and methods of use thereof | F5, F13B, F12 | POLB 616/4885HPRT1 2077/4885P2RY2 4359/4885 |
| US-12565653-B2 | ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof | ATXN2, ATXN2L, ATXN10 | POLB 448/4885HPRT1 1473/4885P2RY2 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.